STRATA Skin Sciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SSKN research report →
Price Chart
About the company
STRATA Skin Sciences, Inc. is an innovative medical technology enterprise dedicated to the development, commercialization, and marketing of advanced products specifically designed for treating a range of dermatologic conditions. The company operates through two main divisions: Dermatology Recurring Procedures and Dermatology Procedures Equipment.
- CEO
- Erica Jordan
- IPO
- 2005
- Employees
- 114
- HQ
- Horsham, PA, US
Get TickerSpark's AI analysis on SSKN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $465
- P/E
- -0.00
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 108.53
- Div Yield
- 0.00%
- Gross Margin
- 59.05%
- Op Margin
- -16.93%
- Net Margin
- -16.97%
- ROE
- -268.41%
- ROIC
- -20.89%
Latest fiscal year · YoY change
- Revenue
- $30.70M-8.5%
- Gross Profit
- $17.88M-6.3%
- Op Income
- $-5,835,000
- Net Income
- $-6,261,000+37.9%
- EPS
- $-1.35-419.2%
- OCF Growth
- -1586.2%
- FCF Growth
- -194.3%
- 52W High
- $1.53
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.09
- Beta
- -0.05
- RSI (14)
- 40
- Avg Volume
- 4.20K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
STRATA said Q3 was pressured by international weakness and tariffs, but recurring U.S. business, device utilization, and the 2027 CPT code expansion are building a longer-term growth setup.· November 13, 2025
- Total revenue was $6.9 million, down 20% year over year, driven mainly by international headwinds.
- Recurring business held up better: global recurring revenue was $5.5 million, up 3%, while U.S. gross code sales rose 4.1% and net U.S. recurring XTRAC revenue rose 2.8%.
- Gross margin was roughly flat and gross profit was $4.2 million, or 60% of revenue.
- Elevate360 was framed as a utilization driver: 99 clinics in the program saw average 7% growth, and average gross billings per device reached $5,981, up 8.5% and the highest since 2022.
- Management emphasized the 2027 expanded CPT codes as a major catalyst, saying the addressable market could more than triple to over 30 million patients.
STRATA reported total revenue of $6.9 million for 2025, down 20% versus 2024. Gross profit was $4.2 million, or 60% of revenue, with gross margin roughly flat year over year. Total operating expenses were $5.4 million versus $6.9 million in the prior year period, helped by the absence of a one-time $1.8 million New York sales tax accrual in 2024 and roughly $680,000 of settlement gains this quarter. Net loss was $1.6 million, or EPS of negative $0.36 per basic and diluted share, versus a net loss of $2.1 million, or EPS of negative $0.51, last year. Adjusted EBITDA was slightly positive, compared with negative $240,000 in the comparable quarter last year. Cash and cash equivalents were $7.1 million at September 30, 2025, after raising $2.2 million net in a registered direct offering. Forward-looking commentary focused on a seasonally stronger fourth quarter of 2025, continued improvement in device utilization, and the expected January 1, 2027 effective date for expanded CPT reimbursement codes; management also said CMS did not want temporary codes for 2026.
Dolev Rafaeli’s tone was constructive and forward-looking. He said the company spent 2025 positioning for future growth through the expanded CPT code set, private-payer outreach, Elevate360, DTC marketing, and international expansion, especially Mexico. He repeatedly framed the 2027 reimbursement changes as pivotal, saying they expand the opportunity to roughly 30 million patients and should create a meaningful increase in procedure revenue. He also highlighted litigation as a source of account recoveries, saying more than 20 LaserOptik buyers have returned or bought direct, representing more than $1 million in annual capital and recurring revenue.
John Gillings focused on the financial bridge between lower top line and improved efficiency. He said revenue was $6.9 million, down 20%, but recurring revenue improved with gross code sales up 4.1%, net U.S. recurring XTRAC revenue up 2.8%, and global recurring revenue up 3% to $5.5 million. Gross profit was $4.2 million, or 60% of revenue, operating expenses fell to $5.4 million from $6.9 million, and net loss improved to $1.6 million with EPS of negative $0.36. He also noted slightly positive adjusted EBITDA, $2.2 million of net proceeds from a common registered direct offering, and $7.1 million of cash and equivalents at quarter-end.
Analysts focused on device utilization, DTC effectiveness, Elevate360, litigation recoveries, TheraClear deployment, and the timing of expanded reimbursement. Management said average gross revenue per device was $5,981, the highest since 2022, and explained the gap between 7% Elevate360 growth and 8.5% overall gross billings growth as a difference between the 99 program accounts and the full 838-clinic base, plus gross-to-net effects. On litigation, management said the damage from false claims affected roughly 75 to 100 accounts, and they are working to win them back. On CMS, management said temporary 2026 codes were not pursued because CMS believed they could create confusion before the January 1, 2027 expanded code rollout.
The bull case from this call is that STRATA appears to be improving recurring utilization even before the reimbursement expansion arrives. Management cited higher gross and net U.S. recurring revenue, higher average revenue per device, positive adjusted EBITDA, and early evidence that Elevate360 and DTC are improving conversion efficiency. The 2027 expanded CPT codes, if implemented as described, could materially broaden the patient base and reimbursement opportunity.
The main risks discussed were international weakness, tariffs, and the fact that total revenue fell 20% year over year. Management also said China softened in the second quarter and international pressure continued in the third quarter. The expanded CPT codes do not take effect until January 1, 2027, and CMS declined to create temporary codes for 2026, so the larger reimbursement upside is not immediate.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 47.0%
- Shares Outstanding
- 4.65M
- Float Shares
- 2.19M
of shares held by institutions
22 13F filers
Buy/sell ratio 0.67. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Broadfin Capital, LLC | 1.84M | ▼ 1.08M |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 25 | Rubinstein Samuel | sell | 5,500 |
| Nov 18, 25 | Rubinstein Samuel | buy | 2,832 |
| Nov 18, 25 | Rubinstein Samuel | buy | 2,168 |
| Nov 17, 25 | Rubinstein Samuel | sell | 7,200 |
| Nov 17, 25 | Rubinstein Samuel | sell | 1,394 |
| May 13, 25 | Gov Shmuel | other | 40,000 |
| May 13, 25 | Gillings John T | other | 30,000 |
| May 13, 25 | Rafaeli Dolev | other | 58,000 |
| Nov 13, 24 | Gillings John T | other | 0 |
| Oct 29, 24 | Allgeier Christina L | other | 20,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SSKN coverage
Recent articles, reports, and earnings notes.
No research on SSKN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SSKN report →STRATA Skin Sciences Appoints Medical Device Commercial Leader Erica Jordan as Chief Executive Officer
globenewswire.com · Jul 28
New Peer-Reviewed Publication Confirms Unprecedented Response Rates for STRATA's Excimer Laser Combined with JAK Inhibitors in Pediatric Vitiligo
globenewswire.com · May 18
Short Interest in Strata Skin Sciences, Inc. (NASDAQ:SSKN) Rises By 89.2%
defenseworld.net · Mar 2
Hims & Hers Health (NYSE:HIMS) & Strata Skin Sciences (NASDAQ:SSKN) Head-To-Head Analysis
defenseworld.net · Mar 1
Critical Comparison: Clover Health Investments (NASDAQ:CLOV) and Strata Skin Sciences (NASDAQ:SSKN)
defenseworld.net · Mar 1
STRATA Skin Sciences Confirms Nasdaq Delisting
globenewswire.com · Feb 19
SSKN Stock Falls Despite Meta-Analysis Backs Excimer Laser's Efficacy
zacks.com · Feb 18
Johns Hopkins Dermatology Expands Advanced Care for Inflammatory and Autoimmune Skin Conditions with Addition of XTRAC® Excimer Laser
globenewswire.com · Feb 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.